INHSU 2017: People Who Use Drugs Should Be Prioritized for Hepatitis C Treatment
- Details
- Category: People Who Inject Drugs
- Published on Thursday, 21 September 2017 00:00
- Written by INHSU
People who use drugs should be given high priority for antiviral treatment as a way to eliminate hepatitis C as a public health concern, according to a statement issued at the 6th International Symposium on Hepatitis Care in Substance Users, held earlier this month in Jersey City.
PAS 2017: Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C
- Details
- Category: Children & Adolescents
- Published on Tuesday, 16 May 2017 00:00
- Written by Liz Highleyman
A 2-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course cured all but one teen with harder-to-treat genotype 3, according to a presentation at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.
CROI 2017: Hepatitis C Treatment Can Be Provided Successfully at Syringe Exchange Sites
- Details
- Category: People Who Inject Drugs
- Published on Thursday, 13 April 2017 00:00
- Written by Liz Highleyman
Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Expanding treatment for this population could reduce hepatitis C virus (HCV) transmission and ultimately help eliminate hepatitis C as a public health threat.
Web Design and Development by